{"DataElement":{"publicId":"6003729","version":"2","preferredName":"Gene Mutation Identification Method Gene Mutation Identification Method Type","preferredDefinition":"The method used to determine the precise order of the nucleotides within a DNA molecule, often used to identify gene mutations.","longName":"mutation_identification_method","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"6002153","version":"1","preferredName":"Gene Mutation Identification Method","preferredDefinition":"change occurring in one gene._The procedure of having an identity established._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","longName":"3226153v1.0:3853556v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"3226153","version":"1","preferredName":"Gene Mutation","preferredDefinition":"change occurring in one gene.","longName":"C18093","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gene Mutation","conceptCode":"C18093","definition":"The result of any gain, loss or alteration of the sequences comprising a gene, including all sequences transcribed into RNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A058FC46-E459-AC72-E040-BB89AD4365D6","latestVersionIndicator":"Yes","beginDate":"2011-04-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-04-07","modifiedBy":"ONEDATA","dateModified":"2011-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3853556","version":"1","preferredName":"Identification Method","preferredDefinition":"The procedure of having an identity established.:A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","longName":"C25737:C71460","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Identification","conceptCode":"C25737","definition":"The procedure of having an identity established.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Method","conceptCode":"C71460","definition":"A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3C9A2B7-10C8-F997-E040-BB89AD432FA1","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435033","version":"1","preferredName":"Techniques","preferredDefinition":"A practiced and regimented skill or series of actions.","longName":"C16847","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87DA-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B4C2D5D-61B5-7D04-E053-F662850AC7EB","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-11","modifiedBy":"HARTLEYG","dateModified":"2017-10-13","changeDescription":"Curated to support HCMI Brain Tumors_10.11.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6003642","version":"2","preferredName":"Gene Mutation Identification Method Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6003642v1.0","context":"OCG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other (specify)","valueDescription":"Specify Other","ValueMeaning":{"publicId":"4888051","version":"1","preferredName":"Specify Other","longName":"4888051","preferredDefinition":"Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"195A90B1-87F5-D292-E050-BB89AD432B03","latestVersionIndicator":"Yes","beginDate":"2015-06-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED95674-0A22-6A76-E053-F662850A1052","beginDate":"2017-10-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Not performed","valueDescription":"Negation Performed","ValueMeaning":{"publicId":"2783448","version":"1","preferredName":"Negation Performed","longName":"2783448","preferredDefinition":"Executed and carried through to completion.:An operation in which a term denies or inverts the meaning of another term or construction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Performed","conceptCode":"C38000","definition":"Executed and carried through to completion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56934A15-43E5-2A2F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-10","endDate":null,"createdBy":"UMLLOADER_CATISSUE","dateCreated":"2008-09-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED95674-0A2C-6A76-E053-F662850A1052","beginDate":"2017-10-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Whole exome sequencing","valueDescription":"Exome Sequencing","ValueMeaning":{"publicId":"3589477","version":"1","preferredName":"Exome Sequencing","longName":"3589477","preferredDefinition":"A procedure that can determine the DNA sequence for all of the exons in an individual.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Whole Exome Sequencing","conceptCode":"C101295","definition":"A procedure that can determine the DNA sequence for all of the exons in an individual.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9B05A6A-D0FA-64E2-E040-BB89AD436E34","latestVersionIndicator":"Yes","beginDate":"2012-09-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED95674-0A36-6A76-E053-F662850A1052","beginDate":"2017-10-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Cancer hotspot panel","valueDescription":"Malignant Neoplasm Genetic Hotspot Panel Reactive Antibody Test","ValueMeaning":{"publicId":"6003645","version":"1","preferredName":"Malignant Neoplasm Genetic Hotspot Panel Reactive Antibody Test","longName":"6003645","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.: A genetic sequence at which mutations occur with an unusually high frequency.: An assessment of the reactivity between host immune cells and donor human leukocyte antigen. This test is most commonly carried out in subjects awaiting transplant. The recipient's blood or serum is mixed with either a panel of lymphocytes from random blood donations or a potential donor's purified human leukocyte antigens (HLA). Host reactivity is scored as a percent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Genetic Hotspot","conceptCode":"C94367","definition":"A genetic sequence at which mutations occur with an unusually high frequency.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Panel Reactive Antibody Test","conceptCode":"C116210","definition":"An assessment of the reactivity between host immune cells and donor human leukocyte antigen. This test is most commonly carried out in subjects awaiting transplant. The recipient's blood or serum is mixed with either a panel of lymphocytes from random blood donations or a potential donor's purified human leukocyte antigens (HLA). Host reactivity is scored as a percent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F779C-9F4F-7144-E053-F662850AE4BD","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED95674-0A40-6A76-E053-F662850A1052","beginDate":"2017-10-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Next generation targeted sequencing","valueDescription":"Next Generation Targeted Sequencing","ValueMeaning":{"publicId":"6003647","version":"1","preferredName":"Next Generation Targeted Sequencing","longName":"6003647","preferredDefinition":"A technique that determines the nucleotide sequence of a pre-specified region of DNA or RNA by using primers that are specific for that region.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Next Generation Targeted Sequencing","conceptCode":"C130177","definition":"A technique that determines the nucleotide sequence of a pre-specified region of DNA or RNA by using primers that are specific for that region.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F779C-9F75-7144-E053-F662850AE4BD","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED95674-0A4A-6A76-E053-F662850A1052","beginDate":"2017-10-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Cancer hotspot panel (specify)","valueDescription":"Malignant Neoplasm Genetic Hotspot Panel Reactive Antibody Test Specify","ValueMeaning":{"publicId":"6840685","version":"1","preferredName":"Malignant Neoplasm Genetic Hotspot Panel Reactive Antibody Test Specify","longName":"6840685","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.: A genetic sequence at which mutations occur with an unusually high frequency.: An assessment of the reactivity between host immune cells and donor human leukocyte antigen. This test is most commonly carried out in subjects awaiting transplant. The recipient's blood or serum is mixed with either a panel of lymphocytes from random blood donations or a potential donor's purified human leukocyte antigens (HLA). Host reactivity is scored as a percent.: Be specific about something; define clearly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Genetic Hotspot","conceptCode":"C94367","definition":"A genetic sequence at which mutations occur with an unusually high frequency.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Panel Reactive Antibody Test","conceptCode":"C116210","definition":"An assessment of the reactivity between host immune cells and donor human leukocyte antigen. This test is most commonly carried out in subjects awaiting transplant. The recipient's blood or serum is mixed with either a panel of lymphocytes from random blood donations or a potential donor's purified human leukocyte antigens (HLA). Host reactivity is scored as a percent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED95674-0A70-6A76-E053-F662850A1052","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED95674-0A89-6A76-E053-F662850A1052","beginDate":"2019-07-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2182370","version":"1","preferredName":"Procedures","preferredDefinition":"Tests, examinations, evaluations used to determine a subject's status or response to intervention.  ","longName":"PROCEDURES","context":"CCR","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7049CF8-1252-211C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-04-01","endDate":null,"createdBy":"DWARZEL","dateCreated":"2004-04-01","modifiedBy":"REEVESD","dateModified":"2004-09-24","changeDescription":"Created initially to support CCR value domain for CTMS. ","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED95674-0A0C-6A76-E053-F662850A1052","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-07-29","modifiedBy":"HARTLEYG","dateModified":"2019-07-29","changeDescription":"Curated to support HCMI Brain Tumors_10.12.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"5806866","version":"1","longName":"Glioblastoma","context":"OCG"},{"publicId":"7589450","version":"1","longName":"DIPG","context":"OCG"},{"publicId":"10000339","version":"1","longName":"LGG","context":"OCG"},{"publicId":"6788377","version":"1","longName":"Renal Cancer","context":"OCG"}]}],"AlternateNames":[{"name":"mutation_identification_method","type":"HCMI Name","context":"OCG"}],"ReferenceDocuments":[{"name":"Mutation identification method","type":"Preferred Question Text","description":"Mutation identification method","url":null,"context":"OCG"},{"name":"HCMI Question Text","type":"Alternate Question Text","description":"By what method was the mutation identified?","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED95A83-1E66-6C83-E053-F662850A936B","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-07-29","modifiedBy":"HARTLEYG","dateModified":"2019-07-29","changeDescription":"Curated to support HCMI Brain Tumors_10.12.17_ghd; versioned due to increase in length and versioning of VD_07.29.19_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}